CN1064533C - 一种治疗由风寒湿痹引起的红肿热痛复方胶囊 - Google Patents
一种治疗由风寒湿痹引起的红肿热痛复方胶囊 Download PDFInfo
- Publication number
- CN1064533C CN1064533C CN96112697A CN96112697A CN1064533C CN 1064533 C CN1064533 C CN 1064533C CN 96112697 A CN96112697 A CN 96112697A CN 96112697 A CN96112697 A CN 96112697A CN 1064533 C CN1064533 C CN 1064533C
- Authority
- CN
- China
- Prior art keywords
- dampness
- wind
- cold
- compound capsule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title claims abstract description 8
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract description 6
- 229960002537 betamethasone Drugs 0.000 claims abstract description 6
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 8
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 6
- 229960003896 aminopterin Drugs 0.000 claims description 6
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 6
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 6
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 4
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000036592 analgesia Effects 0.000 abstract description 2
- XZRKEDHJXXLVSK-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;6-phenylpteridine-2,4,7-triamine Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 XZRKEDHJXXLVSK-UHFFFAOYSA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000009147 positive cooperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
一种治疗由风寒湿痹引起的红肿热痛复方胶囊，由倍他米松、盐酸吡多辛、双氢氯噻嗪、三氨喋呤按比例混合均匀后装入胶囊内所得。本发明对消肿、镇痛有积极的协同效应，疗效显著，毒副作用相互抵消，降至最低服用安全。本发明经四万多例患者服用，显效率100%，无一例有毒副作用反应。
Description
本发明涉及一种药物组合物，具体地说是一种治疗由风寒湿痹引起的红肿热痛复方胶囊。
类风湿性关节炎、风湿性关节炎、风湿性多肌痛、肩周炎、痛风、腰腿痛等，中医称之谓风寒湿痹症，此症、特别是发病时多有红、肿、热、痛的表观症状。常用的抗菌素对此无疗效。镇痛剂、利尿剂(消肿)作用单一，若欲既镇痛又消肿，则需同时服用，但须慎用，因为若不懂得药物代谢动力学和药物之间的相互作用，经则影响疗效，重则对人体造成危害。
本发明提供的具有协同效应的复方胶囊旨在对风寒湿痹引起的红、肿、热、痛症引起到既镇痛解热又消肿祛红的治疗效果。
本发明取倍他米松、盐酸吡多辛、双氢氯噻嗪、三氨喋呤按比例复配混合均匀后装入胶囊内即得复方胶囊。所述的比例如下(重量比)
倍他米松、盐酸吡多辛、双氢氯噻嗪、三氨喋呤=1∶50∶62．5∶62．5。
倍他米粉是镇痛剂，但有引起浮肿、向心性肥胖、高血压、低血钾、恶心、呕吐等副作用；双氢氯噻嗪有利尿消肿、降血压以及抗向心性肥胖等作用；三氨喋呤亦是利尿剂有消肿作用，且可排除尿酸，减轻疼痛，同双氢氯噻嗪并用可增强疗效，并可消除倍他米粉和双氢氯噻嗪的排钾副作用；盐酸吡哆辛可抑制恶心、呕吐。
上述四种药按比例复配在一起是申请人在数十年行医实践中总结出来的，对消肿、镇痛有积极的协同效应，疗效显著，毒副作用相互抵消，降至最低。本发明经四万多名患者服用，显效率100％，无一例有毒副作用反应。本发明原料易得(市场有售)，加工方便。
实施例：
取倍他米松4克，盐酸吡多辛200克，双氢氯噻嗪250克，三氨喋呤250克，混合均匀后装入10，000粒胶囊内即得复方胶囊。每粒胶囊内有70．4毫克混合药粉，日服一次，每次一粒。
为适应胶囊机器包装的需要，可以加入辅料如淀粉等一道混合均匀。辅料加入量以胶囊大小为准。以2号胶囊为例，其容积是270毫克，对上述实施例来说应加入1．996千克淀粉同倍他米松、盐酸吡多辛、双氢氯噻嗪、三氨喋呤一道混合均匀后装入10，000粒胶囊内，每粒胶囊内含70．4毫克混合药粉和199．6毫克淀粉。
Claims (1)
1、一种治疗由风寒湿痹引起的红肿热痛复方胶囊，由镇痛剂、利尿剂复配而成，其特征在于：由倍他米松、盐酸吡多辛、双氢氯噻嗪、三氨喋呤依次按1∶50∶62．5∶62．5比例复配后混合均匀装入胶囊内，每粒胶囊内有效成分70．4毫克。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96112697A CN1064533C (zh) | 1996-10-24 | 1996-10-24 | 一种治疗由风寒湿痹引起的红肿热痛复方胶囊 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96112697A CN1064533C (zh) | 1996-10-24 | 1996-10-24 | 一种治疗由风寒湿痹引起的红肿热痛复方胶囊 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1180520A CN1180520A (zh) | 1998-05-06 |
| CN1064533C true CN1064533C (zh) | 2001-04-18 |
Family
ID=5121568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96112697A Expired - Fee Related CN1064533C (zh) | 1996-10-24 | 1996-10-24 | 一种治疗由风寒湿痹引起的红肿热痛复方胶囊 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1064533C (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0003828D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
-
1996
- 1996-10-24 CN CN96112697A patent/CN1064533C/zh not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 《当代结构药物全集》第一版 1993.1.1 王泽民主编，北京科学技术出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1180520A (zh) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2092074C (en) | Rapidly disintegratable multiparticulate tablet | |
| FI101040B (fi) | Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi | |
| US20110275718A1 (en) | Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same | |
| GB2230185A (en) | Differential release layered pharmaceutical tablet | |
| KR20030009440A (ko) | 조성물 | |
| AU2001260212A1 (en) | Composition | |
| CN102805746B (zh) | 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用 | |
| JP3018160B2 (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤 | |
| Veterans Administration Cooperative Study Group on Antihypertensive Agents et al. | Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension | |
| CN101756990B (zh) | 用于减肥或治疗高血脂症的药物组合物 | |
| EP0100061B1 (en) | Pharmaceutical combination composition and associated method | |
| CN115813874B (zh) | 一种口服三方组合降糖双释片的制备方法及其制剂 | |
| CN1064533C (zh) | 一种治疗由风寒湿痹引起的红肿热痛复方胶囊 | |
| US5035898A (en) | Potassium/magnesium supplement | |
| Ambroso et al. | Treatment of arterial hypertension with nifedipine in patients with chronic renal insufficiency | |
| US4355029A (en) | Combination therapy for rheumatoid arthritis | |
| JP4153124B2 (ja) | 鎮痛剤 | |
| US5229132A (en) | Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time | |
| AU749509B2 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| JP2008056567A (ja) | 胃腸疾患の治療又は予防のための医薬 | |
| JP2000229853A (ja) | 生理痛改善用組成物 | |
| JPS63132834A (ja) | 鎮静剤製剤 | |
| RU2245157C2 (ru) | Биологически активная добавка для профилактики и лечения гриппа "фитогриппин" | |
| JPH0476972B2 (zh) | ||
| EP0207405B1 (en) | Method for making pharmaceutical combination composition in granularly heterogenous solid unit dosage form with enhanced bioavailability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |